Page 335 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 335
32. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014;96(6):655-657.
33. Henricks LM, van Merendonk LN, Meulendijks D, et al. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer. 2018.
34. FDA. U.S. Food and Drug Administration. Label information Xeloda (Capecitabine). 2015; www. FDA.gov. Accessed 29 July 2015.
35. EMA. European Medicines Agency. Xeloda, Procedural steps taken and scientific information after the authorisation. https://www.ema.europa.eu/documents/procedural-steps-after/ xeloda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 14 December 2018.
36. EMA. European Medicines Agency. Xeloda: EPAR - Product information. 2018; European public assessment report for Xeloda Available at: https://www.ema.europa.eu/documents/product- information/xeloda-epar-product-information_en.pdf. Accessed 14 December 2018.
37. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.
38. Deenen MJ, Meulendijks D. Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2017;28(1):184.
39. Danesi R, Del Re M, Ciccolini J, et al. Prevention of fluoropyrimidine toxicity: do we still have to try our patient’s luck? Ann Oncol. 2017;28(1):183.
40. NVMO. Dutch Society of Medical Oncology. Update guideline colorectal carcinoma Medical Oncology 2017. https://www.nvmo.org/wp-content/uploads/2017/06/Richtlijn-CRC-deel- medische-oncologie-update-2017-dd-21-09-2017.pdf. Accessed 21 September 2017.
41. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
42. Loriot MA, Ciccolini J, Thomas F, et al. [Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105(4):397-407.
43. KNMP. Royal Dutch Society for the Advancement of Pharmacy. Fluorouracil/Capecitabine DPD gene activity score and guidelines. [Website]. 2015; https://kennisbank.knmp.nl/article/ farmacogenetica/2552-4893-4894.html. Accessed 05 May 2017.
44. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277-1286.
45. CPIC. Clinical Pharmacogenetics Implementation Consortium®. Guideline for Fluoropyrimidines and DPYD, November 2018 Update. 2018; https://cpicpgx.org/guidelines/guideline-for- fluoropyrimidines-and-dpyd/. Accessed 14 December 2018.
46. Amstutz U, Largiader CR. Genotype-guided fluoropyrimidine dosing: ready for implementation. Lancet Oncol. 2018;19(11):1421-1422.
47. Kleinjan JP, Brinkman I, Bakema R, van Zanden JJ, van Rooijen JM. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study. Anti-cancer drugs. 2019.
13
General discussion
333
